Japan vs Trinidad and Tobago: The number of people with susceptibility test result for rifampicin
Japan
62.2
in 2021
Trinidad and Tobago
59.38
in 2021
Japan rank
108th
Trinidad and Tobago rank
110th
The number of people with susceptibility test result for rifampicin over time
- Japan
- Trinidad and Tobago
How they compare
Japan currently reports 62.2 against 59.38 in Trinidad and Tobago, a difference of 2.82.
The two have swapped places 4 times across 5 shared years of data; in 2017 it was Japan ahead.
Japan ranks 108th and Trinidad and Tobago ranks 110th of 146 countries.
Trinidad and Tobago has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Japan | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 71.84 | 73.58 | 1.73 | Trinidad and Tobago |
| 2020s | 63.07 | 66.49 | 3.42 | Trinidad and Tobago |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Japan or Trinidad and Tobago?
- Japan, at 62.2 against 59.38 in Trinidad and Tobago as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Japan and Trinidad and Tobago?
- 2.82, with Japan ahead.
- How many years of comparable data are there for Japan and Trinidad and Tobago?
- 5 years are reported by both, from 2017 to 2021.
- How do Japan and Trinidad and Tobago rank globally for the number of people with susceptibility test result for rifampicin?
- Japan ranks 108th and Trinidad and Tobago ranks 110th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.